

Conceptus® Inc.

Conceptus(R) to Present at Two Investor Health Care Conferences in June

MOUNTAIN VIEW, Calif., May 19, 2010 (BUSINESS WIRE) -- **Conceptus, Inc. (Nasdaq:CPTS)**, developer of the *Essure(R)* procedure, the first proven non-surgical permanent birth control method available, announced today that it will present at two investor conferences in June 2010. The conferences and presentation dates and times are as follows:

- Mark Sieczkarek, chief executive officer, will present at the 9th Annual Needham Healthcare Conference at 1:20 p.m. (eastern) on Wednesday June 9, 2010 at the New York Palace Hotel.
- Gregory Lichtwardt, chief financial officer, will present at the Jefferies 2010 Global Life Sciences Conference at 2:00 p.m. (eastern) on Thursday June 10, 2010 at the Grand Hyatt Hotel in New York City.

A live webcast of the presentations will be available by going to www.conceptus.com and clicking on the link to Live Webcasts. An archived replay will be available for a period of 30 days.

About the *Essure*^(R) Procedure

The *Essure* procedure, FDA approved since 2002, is a permanent birth control method that can be performed in the comfort of a physician's office in about 9 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Small, flexible micro-inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. *Essure* is 99.74% based on five years of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost may be as low as a simple co-pay.

Three months after the *Essure* procedure, a doctor performs an *Essure* Confirmation Test to confirm that the fallopian tubes are fully blocked, and that the patient can rely on *Essure* for permanent birth control. *Essure* has been proven and trusted by physicians since 2002, with more than 400,000 women worldwide having undergone the *Essure* procedure.

About Conceptus, Inc.

Conceptus, Inc. (NASDAQ:CPTS), is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Mountain View, Calif.-based company manufactures and markets *Essure* permanent birth control. The *Essure* procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East.

Please visit www.essure.com for more information on the *Essure* procedure. Patients may call the *Essure* Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area. Information about Conceptus is available at www.conceptus.com.

©2010. All rights reserved. Conceptus and *Essure* are registered trademarks and your Family is Complete your Choice is Clear is a service mark of Conceptus Inc.

SOURCE: Conceptus, Inc.

Corporate

Conceptus

Gregory Lichtwardt, CFO
(650) 962-4039

glichtwardt@conceptus.com

or

Investor Relations

Lippert/Heilshorn & Associates

Kim Sutton Golodetz

(212) 838-3777

kgolodetz@lhai.com

or

Bruce Voss

(310) 691-7100

bvoss@lhai.com

or

Media

Conceptus

Public Relations

(650) 962-4126

publicrelations@conceptus.com

Copyright Business Wire 2010